References
- Karch SB, editor. Drug Abuse Handbook. 2nd ed. Boca Raton: CRC Press; 2006.
- Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999; 47 : 403 – 12. doi: 10.1046/j.1365-2125.1999.00921.x
- Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 2007;321:389–99. doi: 10.1124/jpet.106.117580
- Yongfang Li, Kantelip JP, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther 2008;12:109–24. doi: 10.1007/BF03256276
- Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid- dependent individuals. Clin Pharmacol Ther 2006;80:682–90. doi: 10.1016/j. clpt.2006.09.011
- Richards-Waugh LL, Primerano DA, Dementieva Y, Kraner JC, Rankin GO. Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism. J Anal Toxicol 2014;38:541–7. doi: 10.1093/jat/bku091
- Sutlovic D, Kljucevic Z, Sliskovic L, Susnjar H, Viskovic I, Definis-Gojanovic M. Methadone maintenance treatment: a 15-year retrospective study in Split-Dalmatia County, Croatia. Ther Drug Monit 2018;40:486–94. doi: 10.1097/FTD.0000000000000519
- Ključević Z, Benzon B, Ključević N, Veršić Bratinčević M, Sutlović D. Liver damage indices as a tool for modifying methadone maintenance treatment: a cross-sectional study. Croat Med J 2018;59:298–306. doi: 10.3325/cmj.2018.59.298
- Bogdanović Z, Marinović-Terzić I, Kuret S, Jerončić A, Bradarić N, Forempoher G, Polašek O, Anđelinović Š, Terzić J. The impact of IL-6 and IL-28B genepolymorphisms on treatment outcome ofchronic hepatitis C infection amongintravenous drug users in Croatia. PeerJ 2016;4:e2576. doi: 10.7717/peerj.2576
- Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski MS, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317–25. doi: 10.1002/hep.21178
- Veršić Bratinčević M, Visković T, Sutlović D. Comparison of the solid phase and liquid-liquid extraction methods for methadone determination in human serum and whole blood samples using gas chromatography/mass spectrometry. Arh Hig Rada Toksikol 2017;68:308–14. doi: 10.1515/aiht-2017-68-2953
- Laboratory of Immunogenomics and Immunoproteomics. Files [displayed 26 August 2020]. Available at http://www.dr-petrek.eu/documents/HWE.xls
- Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008;108:363–74. doi: 10.1097/ALN.0b013e3181642938
- Ahmad T, Sabet S, Primerano DA, Richards-Waugh LL, Rankin G. Tell-tale SNPs: The role of CYP2B6 in methadone fatalities. J Anal Toxicol 2017;41:325–33. doi: 10.1093/jat/bkw135
- Dennis BB, Bawor M, Thabane L, Sohani Z, Samaan Z. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: A systematic review and meta-analysis. PLoS One 2014;9(1):e86114. doi: 10.1371/journal.pone.0086114
- Wu SL, Wang SC, Tsou HH, Kuo HW, Ho IK, Liu SW, Hsu Y-T, Chang Y-S, Liu Y-L. Hepatitis C virus infection influences the S-methadone metabolite plasma concentration. PloS One 2013;8(7):e69310. doi: 10.1371/journal. pone.0069310
- Fonseca F, de la Torre, Diaz L, Pastor A, Cuyàs E, Pizarro N, Khymenets O, Farré M, Torrens M. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PloS One 2011;12:e19527. doi: 10.1371/journal. pone.0019527